{"title":"Milvexian and other drugs targeting Factor XI: a new era of anticoagulation?","authors":"M. Donadini, W. Ageno","doi":"10.4081/btvb.2022.22","DOIUrl":null,"url":null,"abstract":"For almost 90 years, the discovery and development of anticoagulant drugs have focused on maximizing their antithrombotic efficacy while minimizing the risk of bleeding, in addition to providing manageable compounds with predictable and/or monitorable effects [...].","PeriodicalId":186928,"journal":{"name":"Bleeding, Thrombosis, and Vascular Biology","volume":"23 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bleeding, Thrombosis, and Vascular Biology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4081/btvb.2022.22","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Milvexian and other drugs targeting Factor XI: a new era of anticoagulation?
For almost 90 years, the discovery and development of anticoagulant drugs have focused on maximizing their antithrombotic efficacy while minimizing the risk of bleeding, in addition to providing manageable compounds with predictable and/or monitorable effects [...].
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
